




Healthcare Industry News: Grifols
News Release - August 9, 2010
Talecris Biotherapeutics and Grifols Receive FTC Request for Additional Information Regarding Proposed Merger
RESEARCH TRIANGLE PARK, N.C., Aug. 9 (Healthcare Sales & Marketing Network) -- Talecris Biotherapeutics Holdings Corp. (Nasdaq:TLCR ) today announced that Talecris and Grifols S.A. have each received a request for additional information and documentary material, often referred to as a "Second Request," from the U.S. Federal Trade Commission (FTC) in connection with their proposed merger.On June 7, 2010, Grifols and Talecris announced that they had signed a definitive agreement in which Grifols would acquire Talecris for a combination of cash and newly-issued Grifols non-voting shares.
About Talecris: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology, critical care, and hemostasis.
Source: Talecris Biotherapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.